inhA , a Gene Encoding a Target for Isoniazid and Ethionamide in Mycobacterium tuberculosis
The DOI matches its Crossref record; 44 of the 46 references it cites were found in a registry or an index.
Abstract
Isoniazid (isonicotinic acid hydrazide, INH) is one of the most widely used antituberculosis drugs, yet its precise target of action on Mycobacterium tuberculosis is unknown. A missense mutation within the mycobacterial inhA gene was shown to confer resistance to both INH and ethionamide (ETH) in M. smegmatis and in M. bovis . The wild-type inhA gene also conferred INH and ETH resistance when transferred on a multicopy plasmid vector to M. smegmatis and M. bovis BCG. The InhA protein shows significant sequence conservation with the Escherichia coli enzyme EnvM, and cell-free assays indicate that it may be involved in mycolic acid biosynthesis. These results suggest that InhA is likely a primary target of action for INH and ETH.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“inhA was identified as the target of activated INH by an M. smegmatis missense mutation that conferred co-resistance to both INH and Ethionamide (ETH) (129).”
From Mycobacterium smegmatis: The Vanguard of Mycobacterial Research (2023) · cites this paper as [129]
Citations
Cites
Introduction to Protein Structure
Branden, C. I., & Tooze, J. (2012) · Garland Science eBooks · doi:10.1201/9781136969898 · Cited by 2,382
Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis
Telenti, A., Imboden, P., Marchesi, F., Matter, L., Schopfer, K., Bodmer, T., Lowrie, D., Colston, M. J., & Cole, S. (1993) · The Lancet · doi:10.1016/0140-6736(93)90417-f · Cited by 1,337
The catalase—peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis
Zhang, Y., Heym, B., Allen, B., Young, D., & Cole, S. (1992) · Nature · doi:10.1038/358591a0 · Cited by 1,299
Snapper, S. B., Melton, R. E., Mustafa, S., Kieser, T., & Jr, W. R. J. (1990) · Molecular Microbiology · doi:10.1111/j.1365-2958.1990.tb02040.x · Cited by 1,237
Self-citationThe Emergence of Drug-Resistant Tuberculosis in New York City
Frieden, T. R., Sterling, T., Pablos-Mendez, A., Kilburn, J. O., Cauthen, G. M., & Dooley, S. W. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302253280801 · Cited by 939
Tuberculosis in developing countries: burden, intervention and cost.
Murray, C. J. L., Styblo, K., & Rouillon, A. (1990) · PubMed · Cited by 571
[25] Genetic systems for mycobacteria
Jacobs, W. R., Kalpana, G. V., Cirillo, J. D., Pascopella, L., Snapper, S. B., Udani, R. A., Jones, W., Barletta, R. G., & Bloom, B. R. (1991) · Methods in Enzymology · doi:10.1016/0076-6879(91)04027-l · Cited by 433
Self-citationSnider, D. E., & Roper, W. L. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203053261011 · Cited by 382
Combs, D. L., O'Brien, R. J., & Geiter, L. J. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-76-3-112-6-397 · Cited by 315
Takayama, K., Wang, L., & David, H. L. (1972) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.2.1.29 · Cited by 292
Research works printed but not linked: 8
- BEGGS, W.H., AM REV RESPIR DIS 102: 94 (1969).
- GOPINATHAN, K.P., SPECIFICITY OF ISONIAZID ACTION AGAINST MYCOBACTERIA AND A POSSIBLE MECHANISM FOR THE DEVELOPMENT OF DRUG-RESISTANCE, CURRENT SCIENCE 50: 216 (1981).
- GRUMBACH, F, REVUE DE TUBERCULOSE ET DE PNEUMOLOGIE 25: 1365 (1961).
- MIDDLEBROOK, G, AMERICAN REVIEW OF TUBERCULOSIS 65: 765 (1952).
- MURRAY, C. J. L., BULLETIN OF THE INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE 65: 6 (1990).
- Murray, C., Disease Control Priorities in Developing Countries: 233 (1993).
- OFFE, H.A., ZEITSCHRIFT FUR NATURFORSCHUNG 76: 462 (1952).
- PANSY, F, INVITRO STUDIES ON ISONICOTINIC ACID HYDRAZIDE, AMERICAN REVIEW OF TUBERCULOSIS 65: 761 (1952).
Cited by
Items 501–600 of 1,000
Crystal Structures of Enoyl-ACP Reductases I (FabI) and III (FabL) from B. subtilis
Kim, K.-H., Ha, B. H., Kim, S. J., Hong, S. K., Hwang, K. Y., & Kim, E. E. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.12.003 · Cited by 46
Gordhan, B. G., Andersen, S. J., Meyer, A. R. D., & Mizrahi, V. (1996) · Gene · doi:10.1016/0378-1119(96)00350-2 · Cited by 50
Vale, N., Mäkilä, E. M., Salonen, J., Gomes, P. A. C., Hirvonen, J. J., & Santos, H. A. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.02.017 · Cited by 42
Isoniazid metal complex reactivity and insights for a novel anti-tuberculosis drug design
Sousa, E. H. S., Basso, L. A., Santos, D. S., Diógenes, I. C. N., Longhinotti, E., Lopes, L. G. D. F., & Moreira, Í. D. S. (2011) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-011-0848-x · Cited by 42
Kamal, Ä., Azeeza, S., Malik, M. S., Shaik, A. A., & Rao, M. V. (2008) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j36k5k · Cited by 46
Peptide nucleic acids (PNAs): currently potential bactericidal agents.
Narenji, H., Gholizadeh, P., Aghazadeh, M., Rezaee, M. A., Asgharzadeh, M., & Kafil, H. S. (2017) · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · doi:10.1016/j.biopha.2017.06.092 · Cited by 36
Tuberculosis drug discovery in the CRISPR era
Rock, J. M. (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1007975 · Cited by 47
Alcaraz, M., Sharma, B., Roquet, F., Condé, C., Cochard, T., Biet, F., Kumar, V., & Kremer, L. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114531 · Cited by 42
Tuberculose resistente: revisão molecular
Rossetti, M. L. R., Valim, A. R. D. M., Silva, M. S. N., & Rodrigues, V. D. F. S. (2002) · Revista de Saúde Pública · doi:10.1590/s0034-89102002000400021 · Cited by 42
Regulation of Bacterial Responses to Oxidative Stress
Rosner, J. L., & Storz, G. (1997) · Current topics in cellular regulation · doi:10.1016/s0070-2137(97)80007-6 · Cited by 42
Maddry, J. A., Suling, W. J., & Reynolds, R. C. (1996) · Research in Microbiology · doi:10.1016/0923-2508(96)80211-7 · Cited by 43
Argyrou, A., Vetting, M. W., & Blanchard, J. S. (2007) · Journal of the American Chemical Society · doi:10.1021/ja073160k · Cited by 44
Gene Transfer in Mycobacterium tuberculosis : Shuttle Phasmids to Enlightenment
Jacobs, W. R. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.mgm2-0037-2013 · Cited by 42
“For example, while it was feasible to isolate INH-resistant mutants of M. tuberculosis by plating a large number of wild-type bacilli on INH-containing plates, the lack of a DNA transfer system for the tubercle bacillus at the time precluded the mapping of the resistance phenotype to a speci fi c gene.”
BackgroundInfluentialSelf-citationGuardia, A., Gülten, G., Fernandez, R., Gómez, J., Wang, F., Convery, M. A., Blanco, D., Martínez, M., Pérez‐Herrán, E., Alonso, M., et al. (2016) · ChemMedChem · doi:10.1002/cmdc.201600020 · Cited by 41
Thiolactomycin-Based Inhibitors of Bacterial β-Ketoacyl-ACP Synthases with in Vivo Activity
Bommineni, G. R., Kapilashrami, K., Cummings, J. E., Lü, Y., Knudson, S. E., Gu, C., Walker, S. G., Slayden, R. A., & Tonge, P. J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00236 · Cited by 41
Macedo, R., Nunes, A., Portugal, I., Duarte, S., Vieira, L., & Gomes, J. P. (2018) · Tuberculosis · doi:10.1016/j.tube.2018.03.009 · Cited by 40
A Preclinical Candidate Targeting Mycobacterium tuberculosis KasA
Inoyama, D., Awasthi, D., Capodagli, G. C., Tsotetsi, K., Sukheja, P., Zimmerman, M. D., Li, S.-G., Jadhav, R. D., Russo, R., Wang, X., et al. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.02.007 · Cited by 45
“INH and ETH inhibit mycolic acid biosynthesis (Banerjee et al., 1994; Vilcheze et al., 2006).”
BackgroundAlderwick, L. J., Dover, L. G., Veerapen, N., Gurcha, S. S., Kremer, L., Roper, D. I., Pathak, A. K., Reynolds, R. C., & Besra, G. S. (2007) · Protein Expression and Purification · doi:10.1016/j.pep.2007.11.012 · Cited by 48
Novel anti-tuberculosis agents from MCR libraries
Dömling, A. S. S., Achatz, S., & Beck, B. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.04.066 · Cited by 41
Hanoulle, X., Wieruszeski, J., Rousselot‐Pailley, P., Landrieu, I., Baulard, A. R., & Lippens, G. M. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.197 · Cited by 43
Deshpande, D., Pasipanodya, J. G., Mpagama, S. G., Srivastava, S., Bendet, P., Koeuth, T., Lee, P. S., Heysell, S. K., & Gumbo, T. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy609 · Cited by 41
“Once activated, both ethionamide and its structural analogue isoniazid kill Mtb by inhibiting the molecular target InhA; mutations lead to simultaneous resistance to either drug, so that each can generate resistance to the other [9].”
BackgroundIsoniazid induces expression of the antigen 85 complex in Mycobacterium tuberculosis
Garbe, T. R., Hibler, N. S., & Deretic, V. P. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.7.1754 · Cited by 41
Inactivation of the Mycobacterium tuberculosis Antigen 85 Complex by Covalent, Allosteric Inhibitors
Favrot, L., Lajiness, D. H., & Ronning, D. R. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.582445 · Cited by 45
Antimycobacterial Metabolism: Illuminating Mycobacterium tuberculosis Biology and Drug Discovery
Awasthi, D., & Freundlich, J. S. (2017) · Trends in Microbiology · doi:10.1016/j.tim.2017.05.007 · Cited by 40
“Subsequent to this discovery, a genetic strategy was used to identify the target of the activated INH complex as InhA, an enoyl reductase [5].”
Logu, A. D., Uda, P., Pellerano, M. L., Pusceddu, M. C., Saddi, B., & Schivo, M. L. (2001) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/pl00011234 · Cited by 43
“terization of genes that confer resistance in Mycobacterium tuberculosis to primary antimycobacterial agents such as isoniazid [6, 7] or rifampin [8] is not always possible, especially in developing countries, because of the equipment required and the specialized skills”
BackgroundLeung, E. T. Y., Ho, P., Yuen, K., Woo, W. L., Lam, T., Kao, R. Y. T., Seto, W., & Yam, W. C. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.3.1075-1078.2006 · Cited by 44
“katG (2,223) katG-1F, 5 CTTCGGGATCACATCCGTG3 57 to 39 katG-1R, 5 AAGCGGCGCGAACCGCTGC3 396 to 378 katG-2F, 5 GGCATGCAGCGGTTCGCGC3 373 to 391 katG-2R, 5 ACGTCTCGCGAATGTCGAC3 754 to 736 katG-3F, 5 CGCGGCGGTCGACATTCG3 729 to 746 katG-3R, 5 GAACGGGTCCGGGATGGTG3 1104 to 1096 katG-4F, 5 GTTCGGCGGGCCAGGGCGC3 1101 to 1119 katG…”
Recent advances in antituberculous drug development and novel drug targets
Tomioka, H., Tatano, Y., Yasumoto, K., & Shimizu, T. (2008) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2.4.455 · Cited by 40
4Tuberculosis Chemotherapy: Recent Developments and Future Perspectives
Bhowruth, V., Dover, L. G., & Besra, G. S. (2007) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(06)45504-1 · Cited by 46
Rosner, J. L., & Storz, G. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.8.1829 · Cited by 43
“Upon oxidation, the OxyR regulator activates the expression of defense genes which include katG, ahpCF (13), and a gene encoding a small nontranslated RNA designated oxyS (1).”
BackgroundCombating antimicrobial resistance in malaria, HIV and tuberculosis
Duffey, M., Shafer, R. W., Timm, J., Burrows, J. N., Fotouhi, N., Cockett, M. I., & Leroy, D. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00933-4 · Cited by 46
“Among major resistance mechanisms 56,57 , those that directly affect drug targets include SNPs in the rpoB and inhA genes or the embCAB operon, which encode the targets of rifampicin 58 , isoniazid 59 and ethambutol 60 , respectively.”
Tuberculosis Drugs: New Candidates and How to Find More
Sala, C., & Hartkoorn, R. C. (2011) · Future Microbiology · doi:10.2217/fmb.11.46 · Cited by 48
Laborde, J., Deraeve, C., & Bernardes‐Génisson, V. (2017) · ChemMedChem · doi:10.1002/cmdc.201700424 · Cited by 41
Nano-antimicrobials: A New Paradigm for Combating Mycobacterial Resistance
Minakshi, P., Ghosh, M., Brar, B., Kumar, R., Lambe, U. P., Ranjan, K., Manoj, J., & Prasad, G. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190620094041 · Cited by 40
Basso, L. A., Zheng, R., & Blanchard, J. S. (1996) · Journal of the American Chemical Society · doi:10.1021/ja962035y · Cited by 39
Ashek, A., & Cho, S. J. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.10.001 · Cited by 39
Dong, Y., Qiu, X., Shaw, N., Xu, Y., Sun, Y., Li, X., Li, ., & Rao, Z. (2015) · Protein & Cell · doi:10.1007/s13238-015-0181-1 · Cited by 39
“Actually, these are ideal and actual targets for drug discovery (Campbell and Cronan, 2001; Marrakchi et al., 2014): the first-line anti-TB agent isoniazide (INH) and second-line agent ethionamide (ETH) act on InhA (Banerjee et al., 1994); an antibiotic thiolactomycin (TLM) inhibits the activity of KasA and KasB (Krem…”
BackgroundInfluentialThe structure and function of the isoniazid target in M. tuberculosis
Sacchettini, J. C., & Blanchard, J. S. (1996) · Research in Microbiology · doi:10.1016/0923-2508(96)80201-4 · Cited by 40
Crucial components of mycobacterium type II fatty acid biosynthesis (Fas-II) and their inhibitors
Duan, X., Xiang, X., & Xie, J. (2014) · FEMS Microbiology Letters · doi:10.1111/1574-6968.12597 · Cited by 40
“This intermediate product is further reduced by NADH-dependent enoylACP reductase InhA to an ACP-acyl chain (Kikuchi & Kusaka, 1984; Banerjee et al., 1994).”
BackgroundGupta, A., Bhakta, S., Kundu, S., Gupta, M., Srivastava, B. S., & Srivastava, R. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp279 · Cited by 40
“This essential enzyme is required for the elongation of acyl fatty acid precursors of the unique cell wall component mycolic acids through the type-II fatty acid biosynthesis (FAS-II) pathway.(8) The enzymes of the FAS-II pathway have been found to be participating through protein–protein interactions, not only to com…”
BackgroundAdverse effects of oral second-line antituberculosis drugs in children
Schaaf, H. S., Thee, S. A., van der Laan, L., Hesseling, A. C., & Garcia‐Prats, A. J. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1216544 · Cited by 38
“Eto and Pto are prodrugs that, following enzymatic activation by mycobacterial EthA, inhibit InhA, a target shared with isoniazid [39], resulting in inhibition of”
BackgroundAbrahams, K. A., & Besra, G. S. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00261e · Cited by 44
Kenney, T. J., & Churchward, G. (1994) · Journal of Bacteriology · doi:10.1128/jb.176.19.6153-6156.1994 · Cited by 41
Wang, R., & Marcotte, E. M. (2008) · Journal of Proteome Research · doi:10.1021/pr0703066 · Cited by 45
Nicola, G., Smith, C. A., Lucumi, E., Kuo, M. R., Karagyozov, L. K., Fidock, D. A., Sacchettini, J. C., & Abagyan, R. A. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.04.113 · Cited by 38
“ENR was originally identified as a target for Mycobacterium tuberculosis [4,5] and E.”
BackgroundMolecular analysis of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from India
Unissa, A. N., Selvakumar, N., Narayanan, S., & Narayanan, P. R. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.08.013 · Cited by 39
“These enzymes are involved in elongation of fatty acids intermediate in the biosynthetic pathway [5,6].”
Angelova, V. T., Valcheva, V., Pencheva, T., Voynikov, Y., Vassilev, N. G., Mihaylova, R., Momekov, G., & Shivachev, B. L. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.05.011 · Cited by 39
Molecular Genetics of Mycobacteriophages
Hatfull, G. F. (2015) · ASM Press eBooks · doi:10.1128/9781555818845.ch5 · Cited by 40
Potential applications of molecular biology to the study of fish mycobacteriosis
Belas, R., Faloon, P. W., & Hannaford, A. (1995) · Annual Review of Fish Diseases · doi:10.1016/0959-8030(95)00004-6 · Cited by 45
Edwards, B. D., & Field, S. K. (2022) · Drugs · doi:10.1007/s40265-022-01817-w · Cited by 40
Mishra, M. N., & Daniels, L. (2013) · Journal of Bacteriology · doi:10.1128/jb.01724-12 · Cited by 37
Furi, L., Haigh, R., AL-Jabri, Z., Morrissey, I., Ou, H., León‐Sampedro, R., Martínez, J. L., Coque, T. M., & Oggioni, M. R. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01008 · Cited by 38
Vasava, M. S., Bhoi, M. N., Rathwa, S. K., Shetty, S. S., Patel, R. D., Rajani, D. P., Rajani, S. D., Patel, A. R., Pandya, H., & Patel, H. D. (2018) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2018.12.053 · Cited by 37
Multi-Omics Technologies Applied to Tuberculosis Drug Discovery
Goff, A., Cantillon, D. M., Wildner, L. M., & Waddell, S. J. (2020) · Applied Sciences · doi:10.3390/app10134629 · Cited by 39
Chetty, S., Armstrong, T., Kharkwal, S. S., Drewe, W. C., Matteis, C. I. D., Evangelopoulos, D., Bhakta, S., & Thomas, N. R. (2021) · Pharmaceuticals · doi:10.3390/ph14040361 · Cited by 39
“The INH-NAD adduct then binds to the active site of the enoyl reductase (ENR) InhA, its main target, and exerts its inhibitory action [13,14].”
BackgroundMenendez, C., Rodriguez, F., Ribeiro, A., Zara, F., Frongia, C., Lobjois, V., Saffon‐Merceron, N., Pasca, M. R., Lherbet, C., & Baltas, M. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.06.042 · Cited by 40
“To treat MDRTB, the WHO have recommended using second-line drugs such as fluoroquinolones [12], ethionamide [13,14] and cycloserin [15e17].”
MethodTudó, G., Laing, K. G., Mitchison, D. A., Butcher, P. D., & Waddell, S. J. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.219 · Cited by 41
“The primary target of INH-NAD is InhA, an enoyl-ACP reductase, part of the FASII cycle, that is required for mycolic acid synthesis and maintenance of the mycobacterial cell wall structure (15) ((16)).”
BackgroundSaikia, N., & Deka, R. C. (2012) · Journal of Molecular Modeling · doi:10.1007/s00894-012-1534-9 · Cited by 37
Hidden Markov Model Analysis of Motifs in Steroid Dehydrogenases and Their Homologs
Grundy, W. N., Bailey, T. L., Elkan, C., & Baker, M. E. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6193 · Cited by 42
Wang, X., Gu, J., Wang, T., Bi, L., Zhang, Z., Cui, Z., Wei, H., Deng, J., & Zhang, X. (2011) · Molecular Microbiology · doi:10.1111/j.1365-2958.2011.07892.x · Cited by 37
“Like INH, ETH is a pro-drug that requires activation to form adducts with NAD that subsequently inhibit InhA (Banerjee et al., 1994; Baulard et al., 2000; DeBarber et al., 2000; Vannelli et al., 2002; Wang et al., 2007).”
InfluentialEthA/R-Independent Killing of Mycobacterium tuberculosis by Ethionamide
Ang, M. L. T., Rahim, S. Z. Z., de Sessions, P. F., Lin, W., Koh, V. J. W., Pethe, K., Hibberd, M. L., & Alonso, S. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00710 · Cited by 37
“Since InhA is the downstream target of both ETH and INH (Banerjee et al., 1994; Vilchèze et al., 2005), a pre-screen was first conducted to exclude all the ETHR spontaneous mutants harboring mutation(s) in the inhA gene.”
BackgroundRamirez-Busby, S. M., Rodwell, T. C., Fink, L., Catanzaro, D. G., Jackson, R. L., Pettigrove, M. E., Catanzaro, A., & Valafar, F. (2017) · Scientific Reports · doi:10.1038/s41598-017-03452-y · Cited by 36
The Staphylococcus aureus FASII bypass escape route from FASII inhibitors
Morvan, C., Halpern, D., Kénanian, G., Pathania, A., Anba‐Mondoloni, J., Lamberet, G., Gruss, A., & Gloux, K. (2017) · Biochimie · doi:10.1016/j.biochi.2017.07.004 · Cited by 36
Evolution of Phenotypic and Molecular Drug Susceptibility Testing
Cirillo, D. M., Miotto, P., & Tortoli, E. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-64371-7_12 · Cited by 43
Antitubercular Triazines: Optimization and Intrabacterial Metabolism
Wang, X., Inoyama, D., Russo, R., Li, S.-G., Jadhav, R. D., Stratton, T. P., Mittal, N., Bilotta, J. A., Singleton, E., Kim, T., et al. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.10.010 · Cited by 40
“We assayed for resistance of these 17 JSF-2019 resistant strains against pretomanid and the front-line drug isoniazid (INH) which inhibits the essential fatty acid biosynthetic enzyme InhA (Banerjee et al., 1994; Rozwarski et al., 1998a; Vilcheze et al., 2006).”
BackgroundKing, A. C., & Wu, L. (2009) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph13a07s47 · Cited by 36
Barot, K. P., Jain, S. V., Gupta, N., Kremer, L., Singh, S., Takale, V., Joshi, K., & Ghate, M. D. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.06.019 · Cited by 37
Stec, J., Vilchèze, C., Lun, S., Perryman, A. L., Wang, X., Freundlich, J. S., Bishai, W. R., Jacobs, W. R., & Kozikowski, A. P. (2014) · ChemMedChem · doi:10.1002/cmdc.201402255 · Cited by 38
Self-citationQuémard, A., Lanéelle, M., Marrakchi, H., Promé, D., Dubnau, E., & Daffé, M. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00758.x · Cited by 36
Self-citationOld and new drugs for the treatment of tuberculosis in children
Donald, P. R., & Schaaf, H. S. (2007) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2007.04.001 · Cited by 36
Ristow, M., Möhlig, M., Rifai, M., Schatz, H., Feldmann, K., & Pfeiffer, A. F. H. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91351-3 · Cited by 36
Interdependence of mycobacterial iron regulation, oxidative-stress response and isoniazid resistance
Dussurget, O., & Smith, I. (1998) · Trends in Microbiology · doi:10.1016/s0966-842x(98)01307-9 · Cited by 36
Rapid detection of multidrug-resistant tuberculosis
Goyal, M., Shaw, R., Banerjee, D., Coker, R., Robertson, B. D., & Young, D. (1997) · European Respiratory Journal · doi:10.1183/09031936.97.10051120 · Cited by 36
“Mutations at several different loci can give rise to isoniazid resistance [11, 12], but resistance to rifampicin is almost always mediated by mutation of residues within a short stretch of the gene encoding the β-subunit of ribonucleic acid (RNA) polymerase (rpoB) [13, 14].”
BackgroundGong, G., Lee, H., Hoon Kang, G., Shim, Y., Huh, J., & Kwang Khang, S. (2002) · Diagnostic Cytopathology · doi:10.1002/dc.10092 · Cited by 35
Multiplex detection of extensively drug resistant tuberculosis using binary deoxyribozyme sensors
Bengtson, H. N., Homolka, S., Niemann, S., Reis, A. J., Silva, P. E., Gerasimova, Y. V., Kolpashchikov, D. M., & Rohde, K. H. (2017) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2017.02.051 · Cited by 36
“INH resistance can also arise due to SNPs in the promoter or coding region of inhA, a target of INH which encodes enoyl-ACP reductase involved in mycolic acid synthesis (Banerjee et al. 1994; Dessen et al. 1995; Morlock et al. 2003).”
BackgroundGurvitz, A. (2009) · Molecular Genetics and Genomics · doi:10.1007/s00438-009-0474-2 · Cited by 40
“Plasmid constructions DNA manipulations and plasmid constructions were performed according to standard techniques (Ausubel et al. 1989).”
MethodAcyl carrier protein is a bacterial cytoplasmic target of cationic antimicrobial peptide LL-37
Chung, M.-C., Dean, S. N., & van Hoek, M. L. (2015) · Biochemical Journal · doi:10.1042/bj20150432 · Cited by 35
Rapaport, E., Levina, A., Metelev, V., & Zamecnik, P. C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.2.709 · Cited by 35
Logu, A. D., Pellerano, M. L., Sanna, A. M., Pusceddu, M. C., Uda, P., & Saddi, B. (2003) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(02)00350-3 · Cited by 39
“tuberculosis to first-line antituberculous agents such as isoniazid [7] or rifampicin [8] is not always possible, especially in developing countries, because of the equipment required and the specialized skills needed to perform such methods.”
BackgroundMolecular Approaches to the Diagnosis of Tuberculosis
Shinnick, T. M., & Jonas, V. (2014) · ASM Press eBooks · doi:10.1128/9781555818357.ch30 · Cited by 36
Development of New Therapeutics to Meet the Current Challenge of Drug Resistant Tuberculosis
Sheikh, B. A., Bhat, B. A., Mehraj, U., Mir, W. R., Hamadani, S., & Mir, M. A. (2020) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201021666200628021702 · Cited by 37
Pinzi, L., Lherbet, C., Baltas, M., Pellati, F., & Rastelli, G. (2019) · Molecules · doi:10.3390/molecules24142567 · Cited by 37
“However, we decided to focus our attention to the InhA enzyme, which is a validated target of well-known antitubercular drugs [23,24].”
BackgroundReingewertz, T. H., Meyer, T., McIntosh, F. A., Sullivan, J., Meir, M., Chang, Y., Behr, M. A., & Barkan, D. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01899-19 · Cited by 44
“This adduct inhibits the enoyl-[acyl-carrier-protein] reductase (InhA) protein, an essential enzyme for mycolic acid synthesis, thus impairing mycobacterial cell wall synthesis (7, 8).”
BackgroundThe pathogenic mechanism of Mycobacterium tuberculosis: implication for new drug development
Yan, W., Zheng, Y., Dou, C. R., Zhang, G., Arnaout, T., & Cheng, W. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00106-y · Cited by 38
“At present, several effective anti-tuberculosis drugs, such as isoniazid [55], ethionamide, thiacetazone, and delamanid, have been shown to inhibit the biosynthesis of MAs.”
BackgroundMycobacterium tuberculosis gene expression in macrophages
Dubnau, E., & Smith, I. (2003) · Microbes and Infection · doi:10.1016/s1286-4579(03)00090-x · Cited by 39
“tuberculosis [38], based on promoter-driven overexpression of InhA, the major target for isoniazid [39,40].”
BackgroundSelf-citationde Oliveira, J. S., Sousa, E. H. S., de Souza, O. N., Moreira, L., Santos, D. S., & Basso, L. A. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206777698927 · Cited by 48
The Crystal Structure of MCAT from Mycobacterium tuberculosis Reveals Three New Catalytic Models
Li, Z., Huang, Y., Ge, J., Fan, H., Zhou, X., Li, S., Bartlam, M. G., Wang, H., & Rao, Z. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.06.004 · Cited by 34
Cho, S., & Brennan, P. J. (2007) · Tuberculosis · doi:10.1016/j.tube.2007.05.001 · Cited by 34
A Comprehensive Overview of Mycolic Acid Structure and Biosynthesis
Marrakchi, H., Bardou, F., Lanéelle, M., & Daffé, M. (2014) · ASM Press eBooks · doi:10.1128/9781555815783.ch4 · Cited by 37
Marttila, H., Mäkinen, J., Marjamäki, M., & Soini, H. (2008) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-008-0584-5 · Cited by 36
González, N., Torres, M. J., Aznar, J., & Palomares, J. C. (1999) · Tubercle and Lung Disease · doi:10.1054/tuld.1998.0195 · Cited by 35
The Mycobacterium tuberculosis genome at 25 years: lessons and lingering questions
Koleske, B. N., Jacobs, W. R., & Bishai, W. R. (2023) · Journal of Clinical Investigation · doi:10.1172/jci173156 · Cited by 39
Self-citationRamos, R. M., Perez, J. M., Baptista, L. A., & de Amorim, H. L. N. (2012) · Journal of Molecular Modeling · doi:10.1007/s00894-012-1383-6 · Cited by 33
“mutations in several genes including katG, inhA and ahpC [9–14].”
Rodrigues-Junior, V. S., dos Santos, A., dos Santos, A. J., Schneider, C. Z., Calixto, J. Β., Sousa, E. H. S., Lopes, L. G. D. F., Souto, A. A., Basso, L. A., Santos, D. S., et al. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.04.019 · Cited by 33
“tuberculosis 2-trans-enoyl-acyl carrier protein (CoA) reductase enzyme (InhA) [4].”
BackgroundFlipo, M., Frita, R., Bourotte, M., Martínez, M. S., Böesche, M., Boyle, G. W., Derimanov, G. S., Drewes, G., Gamallo, P., Ghidelli, S., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz6280 · Cited by 33
The Rhodococcal Cell Envelope: Composition, Organisation and Biosynthesis
Sutcliffe, I. C., Brown, A. K., & Dover, L. G. (2010) · Microbiology monographs · doi:10.1007/978-3-642-12937-7_2 · Cited by 45
“Completing the cycle thus produces an aliphatic acyl-ACP two carbons longer than its acyl primer (Banerjee et al. 1994).”
BackgroundBroussy, S., Bernardes‐Génisson, V., Quémard, A., Meunier, B., & Bernadou, J. (2005) · The Journal of Organic Chemistry · doi:10.1021/jo051901z · Cited by 33
Sandegren, L., Groenheit, R., Koivula, T., Ghebremichael, S., Advani, A., Castro, E., Pennhag, A. A. L., Hoffner, S., Mazurek, J., Pawlowski, A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016647 · Cited by 35
“Low-level INH resistance of cluster SMI-049 strains is explained by a -15 C to T transition in the promoter region of the inhA gene, which encodes an enoyl acyl carrier protein reductase involved in fatty acid synthesis [33].”
BackgroundRaman, K., Vashisht, R., & Chandra, N. R. (2009) · Molecular BioSystems · doi:10.1039/b905817f · Cited by 35
Bacterial Enoyl-Reductases: The Ever-Growing List of Fabs, Their Mechanisms and Inhibition
Hopf, F. S. M., Roth, C. D., de Souza, E. V., Galina, L., Czeczot, A. D. M., Machado, P., Basso, L. A., & Bizarro, C. V. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.891610 · Cited by 37
Isoniazid Inhibits the Heme-Based Reactivity of Mycobacterium tuberculosis Truncated Hemoglobin N
Ascenzi, P., Coletta, A., Cao, Y., Trezza, V., Leboffe, L., Fanali, G., Fasano, M., Pesce, A., Ciaccio, C., Marini, S., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069762 · Cited by 32
“Other mechanisms of resistance are related to a mutation in the mycobacterial inhA and KasA genes involved in mycolic acid biosynthesis [41–43] and mutations in NADH dehydrogenase [28,44].”
Background
Metadata
- Authors
- Banerjee, A., Dubnau, E., Quemard, A., Balasubramanian, V., Um, K. S., Wilson, T., Collins, D., de Lisle, G., & Jacobs, W. R.
- Affiliations
- Albert Einstein College of Medicine (US)
- Howard Hughes Medical Institute, Albert Einstein College of Medicine, Bronx, NY 10461.
- AgResearch (NZ)
- AgResearch, Wallaceville Animal Research Center, Upper Hutt, New Zealand.
- Venue
- Science
- Published
- 1994-01-14
- Volume
- 263
- Issue
- 5144
- Pages
- 227-230
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2075000963
- Cited by
- 1,389
- References
- 46
- Citations by year
- 2026: 24 · 2025: 32 · 2024: 31 · 2023: 43 · 2022: 49 · 2021: 39 · 2020: 45 · 2019: 52 · 2018: 52 · 2017: 62 · 2016: 45 · 2015: 54 · 2014: 69 · 2013: 39 · 2012: 57
- FWCI
- 46.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5u01ai030189-03)
- National Institute of Allergy and Infectious Diseases (AI 27160, UO1AI30189)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Epidemiology › Mycobacterium research and diagnosis
- Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Microbial Natural Products and Biosynthesis
- Keywords
- inhA gene, isoniazid, ethionamide, Mycobacterium tuberculosis, therapeutic target, drug resistance, missense mutations, mycolic acid biosynthesis, Mycobacterium smegmatis, Mycobacterium bovis BCG, antitubercular agents
- MeSH terms
- Amino Acid Sequence, Bacterial Proteins, Base Sequence, Cloning, Molecular, Drug Resistance, Microbial, Ethionamide, Genes, Bacterial, Isoniazid, Molecular Sequence Data, Mutation, Mycobacterium, Mycobacterium bovis, Mycobacterium tuberculosis, Mycolic Acids, Oxidoreductases, Open Reading Frames, Sequence Alignment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.